EGF and neoplasm: ERL NPs prepared by nanoparticulation using fat and supercritical fluid with a mean size of 250 nm strongly inhibited epidermal growth factor (EGF) signaling and suppressed proliferation of A549, a human NSCLC cells; in vivo study with A549 xenografts in BALB/c nude mice showed that the NPs not only regressed the tumor more efficiently than Tarceva®, but also exhibited more efficient inhibition of lung metastasis than Tarceva®; these NPs showed 5.5-fold higher bioavailability of ERL than Tarceva® [194].